ACM
DCOY

AIGH Capital Management’s Decoy Therapeutics DCOY Stock Holding History

AIGH Capital Management’s Portfolio DCOY Stock Details DCOY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-50
Closed -$1.91M – 57
2021
Q2 		$1.91M Hold
50
– – 0.34% 41
2021
Q1 		$2.66M Buy
50
+8
+19% +$459K 0.56% 37
2020
Q4 		$1.37M Buy
+42
New +$1.23M 0.56% 37

Other funds holding DCOY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KC
Kepos Capital New York $73.4M AUM 4.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
XSC
X-Square Capital Guaynabo, Puerto Rico $394M AUM 44.75% 1-Year Est. Return

AIGH Capital Management's DCOY Position: Q3 2021 in Review

AIGH Capital Management sold out of Decoy Therapeutics (DCOY) in Q3 2021, closing a stake of 50 shares — an estimated $1.91M sold.

AIGH Capital Management first reported a position in DCOY in Q4 2020 and held it in 3 quarters. The position peaked at $2.66M in Q1 2021. 20 funds tracked by Wall St. Rank hold DCOY as of Q3 2021.

  • AIGH Capital Management reported no remaining Decoy Therapeutics position as of Q3 2021 after selling out during the quarter.
  • AIGH Capital Management sold 50 Decoy Therapeutics shares in Q3 2021, an estimated $1.91M.
  • AIGH Capital Management first reported a position in Decoy Therapeutics in Q4 2020 and held it in 3 quarters.
  • AIGH Capital Management's Decoy Therapeutics position peaked at $2.66M in Q1 2021.
  • 20 funds tracked by Wall St. Rank held Decoy Therapeutics as of Q3 2021.

Based on AIGH Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.